BR112020015507A2 - osimertinib para uso no tratamento do câncer de pulmão de células não pequenas - Google Patents

osimertinib para uso no tratamento do câncer de pulmão de células não pequenas Download PDF

Info

Publication number
BR112020015507A2
BR112020015507A2 BR112020015507-1A BR112020015507A BR112020015507A2 BR 112020015507 A2 BR112020015507 A2 BR 112020015507A2 BR 112020015507 A BR112020015507 A BR 112020015507A BR 112020015507 A2 BR112020015507 A2 BR 112020015507A2
Authority
BR
Brazil
Prior art keywords
osimertinib
treatment
patients
chemoradiation therapy
platinum
Prior art date
Application number
BR112020015507-1A
Other languages
English (en)
Portuguese (pt)
Inventor
Anthony Francis Patrick NASH
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR112020015507A2 publication Critical patent/BR112020015507A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
BR112020015507-1A 2018-02-12 2019-02-11 osimertinib para uso no tratamento do câncer de pulmão de células não pequenas BR112020015507A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862629166P 2018-02-12 2018-02-12
US62/629,166 2018-02-12
PCT/EP2019/053311 WO2019155059A1 (en) 2018-02-12 2019-02-11 Osimertinib for use in the treatment of non-small cell lung cancer

Publications (1)

Publication Number Publication Date
BR112020015507A2 true BR112020015507A2 (pt) 2021-01-26

Family

ID=65443828

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020015507-1A BR112020015507A2 (pt) 2018-02-12 2019-02-11 osimertinib para uso no tratamento do câncer de pulmão de células não pequenas

Country Status (15)

Country Link
US (4) US20200368231A1 (https=)
EP (2) EP4431154A3 (https=)
JP (2) JP2021513517A (https=)
KR (2) KR20200119243A (https=)
CN (2) CN116870008A (https=)
AU (2) AU2019219304A1 (https=)
BR (1) BR112020015507A2 (https=)
CA (1) CA3090010A1 (https=)
EA (1) EA202091841A1 (https=)
IL (1) IL276406A (https=)
MA (1) MA51823A (https=)
MX (1) MX2020008395A (https=)
SG (1) SG11202007414XA (https=)
TW (2) TWI868714B (https=)
WO (1) WO2019155059A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3133766A1 (en) 2019-03-29 2020-10-08 Astrazeneca Ab Osimertinib for use in the treatment of non-small cell lung cancer
CN110433296A (zh) * 2019-08-16 2019-11-12 哈尔滨医科大学 一种19f-mr/荧光多模式分子成像及载药的诊疗一体化纳米探针及制备方法和应用
WO2021148396A1 (en) * 2020-01-20 2021-07-29 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
WO2022120197A1 (en) * 2020-12-03 2022-06-09 Emory University Combinations of epidermal growth factor receptor inhibitors and sterol regulatory element-binding protein inhibitors for uses in cancer therapies
WO2022166794A1 (zh) * 2021-02-02 2022-08-11 贝达药业股份有限公司 埃克替尼在非小细胞肺癌术后辅助治疗中的应用
US20240226101A1 (en) * 2021-04-30 2024-07-11 Suzhou Puhe BioPharma Co., Ltd. Pyrimidinylaminobenzenes for lung cancer treatment
CN114917231A (zh) * 2022-05-27 2022-08-19 杭州师范大学 β-榄香稀和奥希替尼药物组合在制备抗肺癌药物上的应用
KR102899565B1 (ko) 2023-02-14 2025-12-11 박주현 좁은 전시공간에서 전시품의 360도 실감 영상투사식 전시장치

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4119551A1 (en) 2011-07-27 2023-01-18 Astrazeneca AB 2-(2,4,5-substituted-anilino)pyrimidine compounds
GB201400034D0 (en) * 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291
EP3191523B1 (en) * 2014-09-08 2019-08-07 Yeda Research and Development Co., Ltd. Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (tki)
WO2016164217A1 (en) * 2015-04-09 2016-10-13 Clovis Oncology, Inc. Therapeutic combinations for treating cancer
WO2017164887A1 (en) * 2016-03-25 2017-09-28 OSI Pharmaceuticals, LLC Pulse dosing regimen and methods for treatment
US10813933B2 (en) * 2016-05-17 2020-10-27 Japanese Foundation For Cancer Research Therapeutic agent for lung cancer that has acquired EGFR-TKI resistance
US20200038398A1 (en) * 2017-03-10 2020-02-06 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors

Also Published As

Publication number Publication date
KR20200119243A (ko) 2020-10-19
JP2023116537A (ja) 2023-08-22
AU2022203007B2 (en) 2024-07-04
EA202091841A1 (ru) 2020-10-28
TW202412804A (zh) 2024-04-01
US20240156815A1 (en) 2024-05-16
WO2019155059A1 (en) 2019-08-15
SG11202007414XA (en) 2020-09-29
US20230226059A1 (en) 2023-07-20
AU2022203007A1 (en) 2022-05-26
CN111683663A (zh) 2020-09-18
EP3752153A1 (en) 2020-12-23
MA51823A (fr) 2021-05-19
KR20260009945A (ko) 2026-01-20
EP4431154A3 (en) 2024-12-11
US20220184076A1 (en) 2022-06-16
CA3090010A1 (en) 2019-08-15
MX2020008395A (es) 2020-09-21
TWI868714B (zh) 2025-01-01
US20200368231A1 (en) 2020-11-26
JP2021513517A (ja) 2021-05-27
IL276406A (en) 2020-09-30
EP4431154A2 (en) 2024-09-18
TW201941773A (zh) 2019-11-01
CN116870008A (zh) 2023-10-13
AU2019219304A1 (en) 2020-09-24

Similar Documents

Publication Publication Date Title
BR112020015507A2 (pt) osimertinib para uso no tratamento do câncer de pulmão de células não pequenas
Banna et al. Predictive and prognostic value of early disease progression by PET evaluation in advanced non-small cell lung cancer
Fleckenstein et al. F-18-FDG-PET confined radiotherapy of locally advanced NSCLC with concomitant chemotherapy: results of the PET-PLAN pilot trial
KR20210144844A (ko) 비-소세포 폐암의 치료에 사용하기 위한 오시머티닙
Zhang et al. Current and future perspectives in unresectable locally advanced esophageal squamous cell cancer
Huot et al. Long-term musculoskeletal consequences of chemotherapy in pediatric mice
Chen et al. Assessing EGFR‐mutated NSCLC with bone metastasis: Clinical features and optimal treatment strategy
Amar et al. Video-assisted thoracoscopic surgery as a first-line treatment for mediastinal parathyroid adenomas: strategic value of imaging
HK40116781A (en) Osimertinib for use in the treatment of non-small cell lung cancer
Hata et al. A phase II study of pemetrexed monotherapy in chemo-naïve Eastern Cooperative Oncology Group performance status 2 patients with EGFR wild-type or unknown advanced non-squamous non-small cell lung cancer (HANSHIN Oncology Group 002)
Hamada et al. Bilateral vocal cord paralysis: pembrolizumab-induced delayed-onset toxicity in a patient with lung adenocarcinoma
Bekaii-Saab Case Study Series
Ziółek et al. Cancer of an unknown primary with PDZRN3-RAF1 fusion and ATR splice site mutation, with atypical chemosensitivity pattern
ul Rasool et al. Osimertinib-related Pulmonary Fibrosis, A case report and review of literature
Luo et al. Ibrutinib Inhibits Tumor Progression, Alleviates Pain, and Protects the Tibia in a Bone Metastasis Model of Lung Cancer
Brugière et al. What can we learn from a negative randomised controlled trial in bronchiolitis obliterans syndrome after lung transplantation?
Yao et al. FRESCO-2: a global Phase III study investigating the efficacy and safety of fruquintinib in metastatic colorectal cancer
Dickie et al. Soft tissue
Stepaniuk et al. Acquired myasthenia gravis associated with oral sarcoma in a dog
Cheng et al. 173P: Vascular endothelial growth factor-C promotes EGFR-TKIs resistance and cancer stemness via SLUG of non-small cell lung cancer
Burris et al. 6547 POSTER SNS-595: Preliminary results of 2 phase 2 second line studies in lung cancer
Pan et al. Successful Therapy of A Critically Ill Nsclc Patient With Uncommon Mutations in Egfr G719x and S768i Genes Using Furmonertinib: A Case Report
Coucke A phase I trial on LBH 589 (panobinostat), a histone deacetylase inhibitor (HDAC i) in combination with external radiotherapy for the treatment of prostate cancer, esophageal cancer and head and neck cancer.
Baik Initial Experience With Fentanyl Iontophoretic Transdermal System in Robotic Thoracic Surgical Patients
Coucke A phase I trial of sunitinib, a tyrosine kinase inhibitor (TKI) combined with ionizing irradiation in rectal cancer

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]